<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989573</url>
  </required_header>
  <id_info>
    <org_study_id>197-08-001</org_study_id>
    <secondary_id>JapicCTI090915</secondary_id>
    <nct_id>NCT00989573</nct_id>
  </id_info>
  <brief_title>A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease</brief_title>
  <official_title>A Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the safety and efficacy of OPC-6535 and determine the
      optimal dose by once-daily oral administration of OPC-6535 at 25 or 50 mg or placebo for 8
      weeks in combination with base treatment (either a fixed oral dose of 5-aminosalicylic acid
      [5-ASA] or a fixed oral dose of 5-ASA plus enteral nutrition) in 180 patients with active
      Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement rate (number of subjects showing clinical improvement / number of subjects evaluated x 100)</measure>
    <time_frame>after 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement rate</measure>
    <time_frame>after 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>after 4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CRP level from the baseline</measure>
    <time_frame>after 4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>after 2, 4, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral administration of placebo once-daily for 8weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-6535 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of OPC-6535 25 mg once-daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-6535 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of OPC-6535 50mg once-daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration of placebo once-daily for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-6535</intervention_name>
    <description>oral administration of OPC-6535 25 mg once-daily for 8 weeks</description>
    <arm_group_label>OPC-6535 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-6535</intervention_name>
    <description>oral administration of OPC-6535 50 mg once-daily for 8 weeks</description>
    <arm_group_label>OPC-6535 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary lesion in either small intestine or large intestine

          -  C-reactive protein (CRP) level above the upper limit of the normal range

          -  Patients who have been receiving a 5-ASA formulation (oral mesalazine) at a fixed dose
             of 2.25 g/day or higher (not exceeding the approved dose) and at a fixed dosing
             regimen

          -  Patients who have not received enteral nutrition or who have been receiving enteral
             nutrition at a fixed intake of 1200 kcal/day or less

        Exclusion Criteria:

          -  Patients with an uncontrolled external fistula (including anal fistula)

          -  Patients with a history of total proctocolectomy or subtotal colectomy

          -  Patients with short bowel syndrome

          -  Patients with an artificial anus

          -  Patients with serious infectious disease (intra-abdominal abscess, etc)

          -  Patients with malignant tumor

          -  Female patients who are pregnant, lactating, or possibly pregnant, or who wish to
             become pregnant during the trial period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsuhisa Saito</last_name>
    <role>Study Chair</role>
    <affiliation>OPCJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyronggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

